Church & Dwight
CHDBusiness Model
source: coverage-next-full ticker: CHD step: "01" title: Business Model & Overview created: 2026-06-03
Step 01 — Business Model & Overview: Church & Dwight Co. (CHD)
1. Executive Summary
Church & Dwight is a $6.2B revenue Consumer Staples company that has compounded at ~5.7% revenue CAGR from 2008 to 2025 through a distinctive M&A-led growth model. Founded in 1846 around ARM & HAMMER baking soda, the company has evolved into a multi-category branded consumer goods platform by systematically acquiring niche-dominant brands in underserved categories, integrating them through its distribution and marketing infrastructure, and growing them above their respective category rates. This "Evergreen Model" has sustained above-peer TSR across multiple decades. [S2]
2. Business Model Canvas
Value Proposition
CHD creates value by:
- Owning niche category leadership — TROJAN (70% U.S. condom share), WATERPIK (75% water flosser), ARM & HAMMER (#1 laundry by wash loads), THERABREATH (#2 mouthwash)
- Dual premium/value positioning — Portfolio spans premium (OXICLEAN, THERABREATH, WATERPIK, HERO) and value (XTRA, ARM & HAMMER basic) tiers to capture consumers across economic cycles
- Acquisition optionality — Consistent M&A pipeline of established consumer brands that management can scale through CHD's distribution, retail relationships, and marketing infrastructure
Revenue Model
| Revenue Source | FY2025 | Notes |
|---|---|---|
| Consumer Domestic | $4,775M (77%) | Household + personal care in the U.S. |
| Consumer International | $1,129M (18%) | Target: grow to 25%+ of total |
| Specialty Products Division (SPD) | $299M (5%) | Sodium bicarbonate for industrial/commercial; steady cash generator |
Revenue is primarily product sales to mass/grocery/drug/club retailers and increasingly e-commerce (24% of consumer sales in 2025, up from 2% in 2015). Recurring consumption categories provide revenue predictability. [S2]
Cost Structure (FY2025)
| Cost Layer | Amount | % of Sales |
|---|---|---|
| Cost of Revenue (COGS) | $3,428M | 55.3% |
| Gross Profit | $2,775M | 44.7% |
| SG&A + Marketing | ~$1,700M (est.) | ~27% |
| Operating Income | $1,078M | 17.4% |
| D&A | $247M | 4.0% |
| EBITDA | $1,325M | 21.4% |
Marketing/advertising is the primary lever: CHD spends approximately 11% of sales on advertising, which it adjusts dynamically based on competitive conditions and brand building needs. SBC is well-controlled at 0.9% of sales. [S1][S3]
3. Value Chain Layer Map
Raw Materials (Surfactants, Sodium Bicarbonate, Plastics, Fragrances)
↓
Manufacturing (CHD-owned plants + 3PL co-manufacturers)
↓
Distribution (Direct to Retailer; limited direct-to-consumer)
↓
Retail Shelf (Walmart/Target/Amazon/Grocery/Drug/Club ~48% top retailers)
↓
Consumer (Household, Personal Care, Professional/Industrial)
Key observations on the value chain:
- CHD is NOT vertically integrated upstream; raw material inputs are broadly available commodities, limiting COGS advantage but also limiting supply risk
- Manufacturing has been upgraded substantially: $450M in capital improvements since 2022 to support supply chain resilience and tariff mitigation
- Retail concentration is high: top 3 customers represent
48% of Consumer Domestic revenue; Walmart is the largest single customer ($1.4B+ est.) - E-commerce channel (Amazon, Walmart.com, direct) grew from 2% (2015) to 24% (2025) and is the primary growth driver — bypassing some traditional retail power
4. Segment Deep Dive
Consumer Domestic ($4,775M, 77%)
The core U.S. segment encompasses:
- Household products: ARM & HAMMER laundry detergent, cat litter, baking soda, cleaning products; OXICLEAN stain fighters; XTRA detergent (value)
- Oral care: WATERPIK, THERABREATH (now including toothpaste launch 2026)
- Personal care: TROJAN, FIRST RESPONSE, NAIR, ORAJEL, BATISTE, HERO, TOUCHLAND (acquired 2025)
- FY2025 Consumer Domestic grew 0.8% organically (reset year); Q1 2026 +4.4% organic
Consumer International ($1,129M, 18%)
International operations span 80+ countries with strongest positions in UK (BATISTE), Europe, Australia, and emerging markets. Management has set an explicit target to grow International from 18% to 25%+ of total revenue, viewing it as the underpenetrated volume opportunity for existing power brands. FY2025 organic growth +5.3%. [S2]
Specialty Products Division ($299M, 5%)
Manufactures and sells sodium bicarbonate and specialty chemical products to industrial, agricultural, pharmaceutical, and animal nutrition customers. Steady, low-volatility cash generator with modest growth. Not a strategic priority for reinvestment; serves as a capital contributor to the rest of the portfolio. [S2]
5. The Evergreen Model — Core Strategic Logic
CHD's Evergreen Model [S4][S5] is a documented M&A and growth playbook:
| Principle | Mechanics |
|---|---|
| Acquire niche leaders | Target established brands with #1 or #2 positions in underserved categories |
| Integrate via CHD infrastructure | Apply CHD's retail relationships, supply chain, and marketing resources |
| Grow above category | Power brands targeted to grow 3–5% organically vs. category 1–2% |
| Portfolio pruning | Exit categories where private label exposure is rising (VMS divestiture 2025) |
M&A track record:
| Acquisition | Year | Brand/Category | Status |
|---|---|---|---|
| Waterpik | 2017 | Water flosser (oral care) | Core power brand; ~75% share |
| Zicam | 2020 | Cold remedy | Sold (part of VMS exit) |
| Hero Cosmetics | 2021 | Acne patches | Core power brand; 19% share, 3x category growth |
| Touchland | 2025 | Premium hand sanitizer | Newest power brand; $656M |
Capital allocation priority: M&A with TSR-accretive targets > CapEx > New Product Development > Shareholder returns.
6. Competitive Positioning Summary
CHD is not competing head-to-head with P&G across its entire business. The strategy is surgical niche dominance: [S6]
- TROJAN operates in a category P&G doesn't compete in
- WATERPIK holds 75% share in oral irrigators where Colgate and P&G have weak positions
- ARM & HAMMER competes with P&G's Tide on wash loads — and wins on volume despite Tide's marketing budget advantage — by leveraging value pricing and ingredient brand trust
- THERABREATH attacks Colgate's premium mouthwash and toothpaste positions from a clinical/fresh-breath angle
This positioning gives CHD sustainable competitive battles it can win with a smaller budget than the mega-CPG firms.
7. Management & Governance Summary
- CEO: Rick Dierker (assumed role in 2025, previously CFO; open-market purchase of $501K in Aug 2025 signals conviction) [S7]
- Former CEO: Matthew Farrell (retired 2025; presided over 2018–2025 period of strong FCF build-up)
- Board: 11 directors, 10/11 independent, Independent Chair Nils Saligram
- Compensation: ~90% variable; tied to organic sales growth, EPS, and TSR
8. Key Investment Variables
| Variable | Current State | Bull Scenario | Bear Scenario |
|---|---|---|---|
| Organic growth | 3–4% FY2026E | Accelerates to 5%+ on portfolio reshaping | Decelerates to 1–2% on consumer weakness |
| Gross margin | 44.7% (FY2025); +100 bps guided | Reaches 46–47% through 2027 | Commodity/tariff shock reverses to 43% |
| Acquisition pipeline | Post-Touchland; balance sheet at 1.4x leverage | Accretive $500M–$1B deal FY2027 | Overpriced acquisition impairs goodwill again |
| Valuation re-rating | Forward P/E 25x | Re-rates to 28–30x on portfolio mix shift | De-rates to 20x on organic deceleration |
Source Index
| ID | Source | Type | Date |
|---|---|---|---|
| S1 | SEC EDGAR XBRL (CIK 0000313927) | Primary / Filing | 2026-06-03 |
| S2 | CHD 10-K FY2025 | Primary / Filing | 2026-06-03 |
| S3 | StockAnalysis.com — CHD financials | Secondary | 2026-06-03 |
| S4 | CHD Analyst Day 2025 (Jan 31, 2025) | Primary / Management | 2026-06-03 |
| S5 | CHD CAGNY 2026 Presentation | Primary / Management | 2026-06-03 |
| S6 | CHD Competitive Landscape Research (see CHD_financials/industry/) | Secondary | 2026-06-03 |
| S7 | CHD DEF 14A 2025 + Form 4 filings | Primary / Filing | 2026-06-03 |
Note: Earnings call transcript analysis not performed — coverage-next-full path uses filings and management presentations.
Financial Snapshot
source: coverage-next-full ticker: CHD step: "04" title: Financial Quality & Adversarial Sweep created: 2026-06-03
Step 04 — Financial Quality & Adversarial Sweep: Church & Dwight Co. (CHD)
1. Financial Statement Quality Assessment
Revenue Recognition
CHD recognizes revenue from product sales to retail customers per ASC 606 upon transfer of control. This is straightforward for a consumer goods company: revenue is recognized when product ships or is delivered to retailer. No complex multi-element arrangements or deferred revenue patterns that would distort reported revenue. [S1][S2]
Revenue quality: HIGH. No adjustments needed.
Gross Margin Adjustments
Reported gross margins are clean. The FY2022 compression (41.9%) and recovery (44.7% in FY2025) are genuine commodity-cycle effects, not accounting-driven distortions. No indication of channel stuffing or unsustainable pricing. [S1]
Gross margin quality: HIGH. Reported figures representative of underlying business.
Operating Income Adjustments
The two significant non-recurring items requiring normalization:
| Year | Non-Recurring Item | Amount | Impact |
|---|---|---|---|
| FY2022 | Commodity + supply chain cost spike | Organic — no write-down, just genuine cost pressure | Depressed gross margin ~200 bps |
| FY2024 | VMS trade name impairment charge | -$357.1M | Depressed FY2024 operating income to $807M; adjusted ~$1,164M |
| Q3 2024 | VMS impairment concentrated in Q3 | -$357.1M | Drove Q3 2024 operating income to -$91.5M; net loss -$75.1M |
Normalized Operating Income Estimates:
| Year | Reported Op. Income | Adjustment | Normalized Op. Income |
|---|---|---|---|
| FY2024 | $807M | +$357M (VMS impairment) | ~$1,164M (19.1% margin) |
| FY2025 | $1,078M | None | $1,078M (17.4% margin) |
FY2025 normalized operating margin (17.4%) is below FY2023 level (18.0%), reflecting the Touchland amortization drag and growth investments. This is a genuine temporary dilution from the $656M acquisition, not a quality concern. [S2][S3]
SBC Analysis
SBC jumped from $32M (FY2022) to $64M (FY2023) — the Hero acquisition-era compensation investment. SBC has stabilized at ~$58–63M (0.9–1.0% of sales), which is below industry median for CPG companies (typically 1.0–1.5%). Not a concern. [S1]
Goodwill & Intangibles
| Year | Goodwill | Other Intangibles | Total Intangibles | % of Assets |
|---|---|---|---|---|
| FY2023 | $2,432M | $3,302M | $5,734M | 66.9% |
| FY2024 | $2,433M | $2,889M | $5,322M | 59.9% |
| FY2025 | $2,628M | $3,512M | $6,140M | 68.9% |
The FY2025 increase in Goodwill (+$195M) and Other Intangibles (+$623M) reflects the Touchland acquisition ($656M net purchase price). The VMS write-down in FY2024 reduced Other Intangibles by ~$357M, bringing them from $3,302M to $2,889M; the subsequent FY2025 Touchland addition rebuilt them to $3,512M. [S1][S2]
Impairment risk assessment: The VMS write-down was specific to a single brand (VITAFUSION/gummies) in a private-label-pressured category. CHD's remaining intangibles are concentrated in HERO (high-growth), THERABREATH (gaining share), WATERPIK (75% share), and TROJAN (70% share) — brands with stronger competitive moats. Near-term impairment risk is low but not zero for BATISTE (losing domestic share). [Judgment]
Working Capital & Cash Conversion
| Metric | FY2025 | FY2024 |
|---|---|---|
| Accounts Receivable | $593M (35 DSO) | $601M (36 DSO) |
| Inventory | $535M (57 DIO) | $613M (67 DIO) |
| Accounts Payable | $732M (78 DPO) | $705M (78 DPO) |
| Net Working Capital | $396M | $509M |
| Cash Conversion Cycle | ~14 days | ~25 days |
Working capital efficiency improved in FY2025 (inventory down $78M as destocking cleared), contributing to the FCF expansion. DPO of ~78 days is typical for large CPG companies with significant retailer leverage. [S3]
2. Adversarial Research Sweep
Investigation of short reports, SEC investigations, lawsuits, accounting irregularities, and reputational risks.
Active Short Positions / Short Reports
No significant active short thesis identified on CHD as of June 2026. CHD short interest is approximately 1.2–1.5% of float, which is minimal for a large-cap Consumer Staples company. No prominent short seller has published a public attack report on CHD in recent years. [S6]
Historical Litigation & Regulatory Actions
| Matter | Status | Materiality |
|---|---|---|
| TROJAN (sexual wellness) — no known product liability mass litigation | Clean | Immaterial |
| ARM & HAMMER cat litter — class actions re: sodium dust/clumping performance | Settled historically; no active cases identified | Immaterial |
| SEC investigation or accounting inquiry | None identified | None |
| FTC/DOJ antitrust (serial M&A) | No known formal investigations | Immaterial |
Conclusion: No material active litigation identified. CHD's legal profile is typical for a large consumer goods company: routine product liability claims resolved through insurance, no pattern of material lawsuits or regulatory enforcement. [S2]
Product Safety Concerns
- TROJAN is an FDA-regulated Class II device (condoms as medical devices); no significant recalls or adverse action history
- ZICAM zinc product litigation resulted in product reformulation (prior to CHD's divestiture of ZICAM); CHD retained the reformulated product but has since divested it — removing this risk
- HERO acne patches are cosmetics/OTC; no material safety concerns identified
- WATERPIK is FDA-registered for dental irrigation; no material recalls
Management Integrity Assessment
- CEO transition (Farrell → Dierker 2025) was planned and disclosed proactively; no abrupt resignation signals
- Farrell share sales ($62M over 6 months): Consistent with documented retirement plan (10b5-1); timing pre-dates retirement confirmation; flagged but not an integrity signal
- Dierker open-market purchase ($501K Aug 2025): Positive conviction signal post-appointment
- Financial guidance track record: FY2025 was CHD's first meaningful guidance downgrade in several years (organic growth from 3–4% to 0–2%); management was transparent in disclosing the headwinds. No evidence of sandbagging or inflated guidance patterns. [S4][S7]
Quality of Acquisition Track Record
CHD's acquisitions have predominantly been value-creative with limited write-down history until the VMS (VITAFUSION) impairment:
| Acquisition | Year | Written Down? | Assessment |
|---|---|---|---|
| Waterpik | 2017 | No | Strong value creation (75% share) |
| THERABREATH | 2021 | No | Strong value creation (#2 mouthwash) |
| Hero Cosmetics | 2021 | No | Strong value creation; international expansion |
| VITAFUSION / VMS brands | 2012-era + Hero-era | YES ($357M FY2024) | Private label disruption caused impairment |
| FLAWLESS | 2019 | Divested 2025 | Disappointing; divested |
| TOUCHLAND | 2025 | Too early to assess | Management: premium personal care alignment |
One meaningful impairment in 15+ acquisitions is a strong track record. VITAFUSION was the exception, not the rule. [S2][Judgment]
Revenue Quality / Channel Check
No evidence of channel stuffing or unsustainable sell-in. FY2025 retail destocking (Consumer Domestic organic ~0.4%) confirmed end-consumer demand was soft, not pump-priming inventory at retail. Q1 2026 organic acceleration (+5%) with volume-driven growth across all three divisions confirms the destocking was a one-time inventory cycle, not demand structural deterioration. [S4]
3. Key Financial Quality Conclusion
| Dimension | Rating | Notes |
|---|---|---|
| Revenue recognition | Clean | Standard CPG; no concerns |
| Gross margin | Clean | Commodity cycle, not accounting |
| Non-recurring items | Identified | FY2024 VMS impairment; normalized |
| SBC | Acceptable | 0.9% of sales; not dilutive |
| Working capital | Improving | Destocking drove FCF expansion |
| Intangibles / goodwill | Elevated | 68% of assets; M&A model; one impairment |
| Litigation / regulatory | Clean | No material active matters |
| Management integrity | Positive | Dierker conviction buy; no red flags |
| Overall quality | HIGH | Adjust FY2024 for impairment; FY2025 clean |
Source Index
| ID | Source | Type | Date |
|---|---|---|---|
| S1 | SEC EDGAR XBRL (CIK 0000313927) | Primary | 2026-06-03 |
| S2 | CHD 10-K FY2025 + FY2024 | Primary | 2026-06-03 |
| S3 | StockAnalysis.com | Secondary | 2026-06-03 |
| S4 | CHD Q1 2026 Earnings Release (8-K) | Primary | 2026-06-03 |
| S5 | CHD DEF 14A 2025 | Primary | 2026-06-03 |
| S6 | Short interest data, competitive research | Secondary | 2026-06-03 |
| S7 | Form 4 insider transactions | Primary | 2026-06-03 |
Note: Earnings call transcript analysis not performed — coverage-next-full path. Commentary on management tone sourced from 8-K press releases and investor presentations.
Recent Catalysts
source: coverage-next-full ticker: CHD step: "12" title: Bull vs. Bear — Catalysts & Analyst Debate created: 2026-06-03
Step 12 — Bull vs. Bear: Church & Dwight Co. (CHD)
Note: Earnings call transcript analysis not performed (coverage-next-full path). The bull/bear debate below is inferred from analyst consensus notes, investor presentation disclosures, press releases, and analyst rating actions. The debate reflects real positions observed in public sources.
1. The Core Investment Debate
The Church & Dwight investment debate centers on a single tension: a premium multiple for modest organic growth. At 25x forward P/E and 17.8x EV/EBITDA, the market prices CHD as a consistent 6–8% EPS compounder. Bulls believe this is achievable via portfolio reshaping (higher-growth brands + gross margin expansion + buybacks). Bears believe the multiple is too high for 3–4% organic growth with material execution risk on new initiatives (Touchland, TheraBreath toothpaste). [S3][S6]
2. Analyst Rating Landscape
| Stance | Count | Price Targets |
|---|---|---|
| Strong Buy / Buy | 10 of 21 | $106–$115 (RBC $114, Goldman $111, TD Cowen $112) |
| Hold / Neutral | 9 of 21 | $95–$105 |
| Sell / Underweight | 2 of 21 | $74–$79 (Barclays $79) |
| Consensus Average Target | — |
The 21-analyst distribution is roughly split: 47% bullish, 43% neutral, 10% bearish. This is a contested valuation, not a consensus buy. [S6]
3. Bull Case Arguments
Bull Argument 1: Portfolio Reshaping Creates a Higher-Quality, Higher-Growth Compounder
The VMS divestiture (private label competition, declining margins) and divestitures of FLAWLESS/Spinbrush mark a genuine portfolio quality improvement. The new portfolio — anchored by HERO (+3x category growth), THERABREATH (#2 mouthwash, toothpaste launch), TOUCHLAND (premium personal care), and WATERPIK (75% share, hardware recurring revenue) — has structurally better organic growth prospects than the old portfolio. If this mix shift is fully reflected, mid-single-digit organic growth is achievable, not just 3–4%, and the multiple should expand rather than contract. [S5][Judgment]
Supporting data: Q1 2026 organic growth of +5% (above full-year 3–4% guidance) with volume-driven growth across all three segments. THERABREATH mouthwash at 22% share (all-time high). HERO growing at 3x category rate. Both suggest portfolio reshaping thesis is working. [S4]
Bull Argument 2: Gross Margin Expansion Trajectory Has Further to Go
Gross margin of 44.7% (FY2025) is recovering from the 2022 trough (41.9%) but remains below the 45–47% range that CHD argues is structurally appropriate for its portfolio mix. The removal of VMS (lower gross margin due to private label competition) and addition of TOUCHLAND (premium personal care, presumably 60–70%+ gross margins) should mix-shift the portfolio toward higher margins. Additionally, the completed $450M manufacturing investment should reduce per-unit costs and enhance resilience. Management guides +100 bps in FY2026 alone. If gross margin reaches 46–47% by FY2027–FY2028, this adds ~$120–180M of annual EBITDA at current revenue. [S5]
Bull Argument 3: Valuation Near Historical Lows — Asymmetric Risk/Reward
CHD's EV/EBITDA of 17.8x compares to a 10-year median of ~19.3x. The stock is trading near the bottom third of its historical valuation range — arguably a "better" CHD (post-VMS cleanup, higher FCF, proven management succession) at a lower-than-average multiple. If CHD re-rates to its historical median, the target price would be ~$107–112 (approximately +10–15% from $96). [S3]
4. Bear Case Arguments
Bear Argument 1: Premium Valuation on Decelerating Organic Growth Is Unsustainable
At 25x forward P/E and a PEG ratio of ~3.4x, CHD is priced as if it's growing 8–10% EPS annually for many years. But the underlying organic growth rate (3–4% guided FY2026) leaves almost no margin for error. If organic misses — as it did in FY2025 (0–2% vs. initial 3–4% guidance) — the multiple will compress. The EPS growth projected for FY2026 (+21.8% consensus) is almost entirely due to the easy FY2025 comp, not durable acceleration. Stripping this one-time normalization, the forward growth rate is 5–8% EPS — arguably already priced in at 25x. [S3]
Supporting data: Barclays maintains Underweight with $79 target (17.5% downside) specifically citing premium multiple on modest organic growth. Wells Fargo lowered target to $105 citing limited near-term upside. [S6]
Bear Argument 2: Reported Revenue Decline Masks Underlying Deceleration
FY2026 reported revenue is guided at -1.5% to -0.5% despite 3–4% organic growth. The portfolio divestitures (VMS, Spinbrush, Flawless) collectively removed ~$250–300M of revenue that must be replaced by organic growth or Touchland. If Touchland underperforms integration targets, reported revenue could miss 3–4% organic on a net basis, creating a top-line headline miss even with underlying brand health intact. Headline misses historically drive multiple compression for premium-valued Consumer Staples stocks. [Judgment]
Bear Argument 3: Touchland Acquisition Creates Execution Risk and Balance Sheet Drain
At $656M + $159M earnout ($815M total), Touchland was acquired at 5x+ revenue for a premium DTC personal care brand. CHD has proven it can scale traditional CPG brands, but TOUCHLAND is a different animal: DTC-native, social-media-driven, premium fragrance-wellness positioning. If CHD's mass CPG distribution model dilutes the brand's premium cachet (as has happened with other DTC brands acquired by legacy CPG), the earnout of $159M may not be triggered, growth disappoints, and a goodwill impairment risk (reminiscent of VMS) emerges in 2–3 years. Combined with the $900M FY2025 buyback, CHD deployed $1.8B in capital in a single year — leaving less cushion for the next acquisition cycle. [Judgment, A05]
5. Thesis-Deciding Variables
The outcome of the bull-bear debate hinges on 3–4 variables observable over the next 12–24 months:
| Variable | Bull Outcome | Bear Outcome | Expected Timeline |
|---|---|---|---|
| FY2026 organic growth vs. 3–4% guide | Beats (4–5%) — Q1 2026 +5% suggests possible | Misses (1–2%) — FY2025 miss pattern repeats | Q3–Q4 2026 earnings |
| THERABREATH toothpaste launch metrics | Early market share traction; $50M+ Year 1 | Slow launch; limited distribution; no meaningful share | H2 2026 → FY2027 |
| Touchland FY2026 revenue vs. earnout target | On track for $159M earnout | Misses earnout; impairment risk emerges | FY2026 annual report |
| Gross margin trajectory | Reaches 46%+ in FY2026 | Tariff/commodity resurgence limits to 44–45% | Q3 2026 earnings |
6. Bull Case Summary — 3 Bullets
- Portfolio reshaping is generating real results: Q1 2026 organic +5%, 4/8 power brands gaining share, THERABREATH at all-time high share (22%), HERO at 19% with international expansion — the new CHD is a better-quality compounder than the pre-VMS portfolio at a relatively modest (~18x EV/EBITDA) multiple
- Gross margin recovery to 46–47% adds $120–180M of structural EBITDA and expands per-share FCF toward $5.50–6.00, making the current P/FCF of 18x look cheap on a 2–3 year view
- CEO conviction buy ($500K open-market), 29 years of consecutive dividend growth, and conservative 1.4x leverage give downside protection at current prices — even if growth disappoints, the FCF floor ($1.0B+/year) and balance sheet provide a margin of safety
7. Bear Case Summary — 3 Bullets
- 25x forward P/E with a PEG of 3.4x is structurally vulnerable — if organic growth slips to 1–2% (as in FY2025), the market will re-rate toward 20–22x EV/EBITDA and the stock falls 15–20% to $78–83 range, confirming Barclays' target
- Touchland is the portfolio's biggest unknown: a $815M bet on a DTC hand sanitizer brand — if CHD's mass CPG distribution model dilutes the premium cachet or earnout targets are missed, a VMS-style impairment in 2–3 years is not inconceivable
- Reported revenue declining in FY2026 (-1.5% to -0.5%) despite organic growth sounds defensive — the true top-line trajectory (post-divestitures) makes it difficult to construct a compelling revenue acceleration story that the Street can value on a forward P/S or revenue-growth basis
Source Index
| ID | Source | Type | Date |
|---|---|---|---|
| S1 | CHD 10-K FY2025 | Primary | 2026-06-03 |
| S2 | StockAnalysis.com | Secondary | 2026-06-03 |
| S3 | Analyst consensus: MarketBeat, StockTitan, GuruFocus | Secondary | 2026-06-03 |
| S4 | CHD Q1 2026 Earnings Release (8-K) | Primary | 2026-06-03 |
| S5 | CHD CAGNY 2026 + Analyst Day 2025 | Primary | 2026-06-03 |
| S6 | Analyst rating actions: RBC, Goldman, Barclays, Jefferies, TD Cowen, Wells Fargo | Secondary | 2026-06-03 |
Note: Earnings call transcript analysis not performed. Bull/bear debate inferred from written analyst commentary and management press releases.
Full Research Available
This primer covers steps 1–3 of 21. The full deep dive includes moat analysis, DCF valuation, bull/bear scenarios, management quality, earnings transcript analysis, competitive positioning, returns on capital, institutional/insider activity, and an investment memo.